Concepedia

Michael Jäger

MJ

21

Publications

1.5K

Citations

19

H-Index

1997

Active since

Affiliations

Pharmalog (Germany)(Current)

Neovii Biotech (Germany)

Ludwig-Maximilians-Universität München

Charité - Universitätsmedizin Berlin

University of Regensburg

Michael Jäger is an author at Pharmalog (Germany) specializing in medicine, tumor microenvironment, and tumor biology.

ORCID

Top concepts

Publications per year

1997–2022

21

Publications

21

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

Alexander Burges, Pauline Wimberger, Carolin Kümper et al. · Clinical Cancer Research · 2007 · 253 citations

Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

Philipp Kiewe, Stephan Hasmüller, Steffen Kahlert et al. · Clinical Cancer Research · 2006 · 194 citations · Full text

Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)

Michael Jäger, A. Schoberth, Peter Ruf et al. · Cancer Research · 2011 · 116 citations · Full text

, , +21

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

Peter Ruf, Olivier Gires, Michael Jäger et al. · British Journal of Cancer · 2007 · 100 citations · Full text

The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2

Michael Jäger, A. Schoberth, Peter Ruf et al. · Cancer Research · 2009 · 93 citations · Full text

, , +15

Rows per page

1–5 of 21